GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hangzhou AGS Medtech Co Ltd (SHSE:688581) » Definitions » EBIT

Hangzhou AGS Medtech Co (SHSE:688581) EBIT : ¥317.9 Mil (TTM As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Hangzhou AGS Medtech Co EBIT?

Hangzhou AGS Medtech Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ¥85.1 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥317.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hangzhou AGS Medtech Co's annualized ROC % for the quarter that ended in Sep. 2024 was 117.22%. Hangzhou AGS Medtech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 184.43%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hangzhou AGS Medtech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 8.10%.


Hangzhou AGS Medtech Co EBIT Historical Data

The historical data trend for Hangzhou AGS Medtech Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou AGS Medtech Co EBIT Chart

Hangzhou AGS Medtech Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 61.28 51.71 305.47 165.66 251.72

Hangzhou AGS Medtech Co Quarterly Data
Dec17 Dec18 Dec19 Jun20 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.10 87.64 61.08 84.02 85.14

Competitive Comparison of Hangzhou AGS Medtech Co's EBIT

For the Medical Devices subindustry, Hangzhou AGS Medtech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hangzhou AGS Medtech Co's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Hangzhou AGS Medtech Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hangzhou AGS Medtech Co's EV-to-EBIT falls into.


;
;

Hangzhou AGS Medtech Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥317.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hangzhou AGS Medtech Co  (SHSE:688581) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hangzhou AGS Medtech Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=307.824 * ( 1 - 14.25% )/( (221.559 + 228.822)/ 2 )
=263.95908/225.1905
=117.22 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2317.316 - 81.544 - ( 2014.213 - max(0, 94.248 - 2130.707+2014.213))
=221.559

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2407.873 - 92.763 - ( 2086.288 - max(0, 110.286 - 2213.976+2086.288))
=228.822

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Hangzhou AGS Medtech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=340.564/( ( (162.684 + max(21.218, 0)) + (169.263 + max(16.144, 0)) )/ 2 )
=340.564/( ( 183.902 + 185.407 )/ 2 )
=340.564/184.6545
=184.43 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(58.272 + 49.51 + 7.6839999999997) - (81.544 + 0 + 12.704)
=21.218

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(47.757 + 56.517 + 22.156) - (92.763 + 0 + 17.523)
=16.144

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hangzhou AGS Medtech Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=317.88/3926.550
=8.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hangzhou AGS Medtech Co EBIT Related Terms

Thank you for viewing the detailed overview of Hangzhou AGS Medtech Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Hangzhou AGS Medtech Co Business Description

Traded in Other Exchanges
N/A
Address
No. 6 Kangxin Road, Building 597, Building 5, Yuhang District, Zhejiang Province, Hangzhou, CHN, 311106
Hangzhou AGS Medtech Co Ltd is engaged in Research & Development, production, and sales of endoscopic minimally invasive diagnosis and treatment devices. The company upholds the core values of create, insist, share, and providing patients and clinicians with safer and more efficient minimally invasive endoscopic devices, helping patients reduce pain and medical costs.
Executives
Chen Jun Can senior management
Li Peng Core technical personnel
Han Chun Qi Directors, senior managers, core technical personnel
Sheng Yue Yuan Director
Zhang Qin Hua senior management
Zhang Cheng Director

Hangzhou AGS Medtech Co Headlines

No Headlines